

Hospital Clinical Data Network and Research Organization Collaboration for Analysis of Infection Burden in Immunocompromised Patients in France using Real-World Electronic Medical Record Data

Presenting Author: Dan Poscover

Affiliation: Graticule

Conference: ISPOR 2026, May 18th

Conflict of Interest Disclosure



The authors declare that this study received funding from AstraZeneca.

The authors declare no financial or personal relationships with other people or organizations that could inappropriately influence the work reported in this study

Two strategies to access EU real-world data and why a combination approach delivers the most



Europe's hospital networks hold millions of longitudinal patient records **but.....**



- Site relationships, technical pipelines, and regulatory expertise are required to navigate access to EU data at scale
- EU data cannot be licensed off the shelf- every hospital requires individual contracting, ethics approval, and compliant data transfer

We explored both pathways: Federated or Trusted Research Environments

Federated Initiatives



Federated initiatives
provide breadth

**Trusted Research
Environment**



Trusted research
environments unlock depth

And...

*We use a
combination
approach*



**Endurance
Network**

Endurance Immunocompromised Research Network: Enabling Rapid Multi-Site RWE Across the EU




Endurance network unites healthcare professionals and researchers to foster impactful research



Multiple Countries

Italy, France, Spain and growing



Multiple Sites

30+ hospital and data aggregator engagements



Patient Cohort

5M IC patients with row-level data access

- ENDURANCE is a premier global network for immunocompromised (IC) patient research
- Originally established to study COVID-19 outcomes in IC patients (AstraZeneca-funded)
- Evolved into a pan-pathogen network covering SARS-CoV-2, influenza, RSV, and hMPV

Within the Endurance network, HUGO one of the first activated site — demonstrating that the ENDURANCE model works

How we enabled research-ready EMR access in western France




One of the anchor networks within ENDURANCE , a federation of 6 university hospitals in western France, built on the eHOP® data model



RWD study conducted at:

- Objective: Study real-world infection burden among immunocompromised patients using research-ready EMR data
- 4 HUGO hospitals contributed data (Dec 2021 – Oct 2023)
- Outcomes measured: SARS-CoV-2, influenza, RSV, hMPV infection rates by IC subgroup



30,150
IC patients

≥12 yrs · Dec 2021–Oct 2023

4

hospitals
HUGO network, France

11.5

months
median follow-up

54.7%

male
45.3% female


64.4

yrs median age
range 12–101

Analysis Results: Cohort Profile




IC Patients Profile



Immunosuppressive or B-cell depleting therapy accounts for the largest IC subgroup (55.5%), followed by hematologic malignancy (27%) and organ transplantation (21%)

Infection Profile of IC Patients




SARS-CoV-2 dominates the infection burden across all IC subgroups




Analysis Results: Infection Burden & Clinical Outcomes*

Rates of infection were 107.8 cases per 1,000 person-years for SARS-CoV-2, 12.4 for influenza, 9.3 for hMPV, and 5.4 for RSV





Research Impact: The Process-to-Value Journey



For the full dataset and methodology, scan here to access our digital evidence hub



THANK YOU

Dan Poscover

dposcover@graticule.life